发明名称 |
PREDICTION AND TREATMENT OF HEART FAILURE |
摘要 |
Chronic activation of the β-Adrenergic Receptor (β-AR) can have deleterious effects on the heart, and animal models over-expressing the β-AR develop heart failure. In the classical β-AR pathway, activation of the receptor results in increased cyclic AMP (cAMP) levels. However, β-ARs are desensitized in the failing heart and cAMP levels are decreased. Phosphodiesterase 3A (PDE3A) hydrolyzes cAMP in certain subcellular compartments in cardiac myocytes, regulating cAMP levels and subsequent protein kinase A mediated cell signaling. By virtue of being freely diffusable intracellularly and being reduced in failing myocardial tissue, cAMP is reduced in certain important cardiac myocyte subcellular compartments such as the microdomain occupied by phospholamban. |
申请公布号 |
WO2015054045(A8) |
申请公布日期 |
2015.06.11 |
申请号 |
WO2014US58962 |
申请日期 |
2014.10.03 |
申请人 |
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODYCORPORATE |
发明人 |
BRISTOW, MICHAEL;SUCHAROV, CARMEN;TAYLOR, MATTHEW;SLAVOV, DOBROMIR |
分类号 |
C12Q1/68 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|